<DOC>
	<DOCNO>NCT01551706</DOCNO>
	<brief_summary>This Randomized , Double-blind , Placebo-controlled , Pilot Study Evaluate Effect ENI Patented Whole Grape Extract Antioxidant Status .</brief_summary>
	<brief_title>Pilot Study Evaluate Effect ENI Patented Whole Grape Extract Antioxidant Status</brief_title>
	<detailed_description>This study investigate effect ENI Patented Whole Grape Extract versus placebo antioxidant status . The primary objective determine antioxidant status measure total antioxidant capacity superoxide dismutase ( SOD ) blood 8-OHdG 8-isoprostane first morning void urine sample prior six week supplementation ENI Patented Whole Grape Extract . Secondary objective include assessment oxidize LDL ( oxLDL ) safety evaluation : 1. oxLDL 2 . Safety laboratory test : CBC , electrolytes , glucose , creatinine , eGFR , AST , ALT , GGT , bilirubin 3 . Vital sign : heart rate blood pressure 4 . Adverse event</detailed_description>
	<mesh_term>Antioxidants</mesh_term>
	<criteria>1 . Male female 18 65 year age 2 . If female , subject child bear potential . Defined female hysterectomy oophorectomy , bilateral tubal ligation postmenopausal ( natural surgically &gt; 1 year since last menstruation ) . OR Female subject childbearing potential must agree use medically approve method birth control negative urine pregnancy test result . Acceptable method birth control include : Doublebarrier method ( condom spermicide diaphragm spermicide ) Hormonal contraceptive include oral contraceptive , hormone birth control patch ( Ortho Evra ) , vaginal contraceptive ring ( NuvaRing ) , injectable contraceptive ( DepoProvera , Lunelle ) , hormone implant ( Norplant System ) Intrauterine device Vasectomy partner ( show successful per appropriate followup ) Abstinence 3 . One follow condition : Prehypertension define diastolic blood pressure 8089 mmHg systolic blood pressure 139 low screening BMI 25.0 34.9 kg/m2 Prediabetes define fast plasma glucose 5.2 6.9 mmol/L 4 . Subjects smoker agree report smoke habit visit plan change smoke habit study . 5 . Has give voluntary , write , inform consent participate study 1 . Women pregnant , breastfeeding , plan become pregnant course trial 2 . Subject clinically significant medical condition include cardiovascular disease , hypertension ( systolic blood pressure ≥ 140 mmHg , diastolic blood pressure ≥ 90mmHg ) , diabetes , liver kidney disease 3 . Use medication treatment hypertension 4 . Use medication vasodilation , include nitric oxide release patch 5 . Use medication erectile dysfunction 6 . Use medication ( prescribed counter ) weight loss 7 . Use statin , fibrates , niacin , medication treatment hypercholesterolemia 8 . Use anticoagulant 9 . Use illicit drug history drug alcohol abuse past 5 year ( currently 2 standard alcoholic drink per day ) 10 . Use natural health product ( NHPs ) /dietary supplement know significant antioxidant activity within 2 week prior baseline course study include limited vitamin A , C , E , selenium zinc . 11 . Participation clinical research trial within 30 day prior baseline 12 . Clinically significant abnormal laboratory result screen include AST , ALT and/or bilirubin &gt; 2 x ULN Serum creatinine &gt; 1.5 x ULN eGFR &lt; 60 hemoglobin &lt; 140 g/L male &lt; 123 g/L female 13 . Allergy sensitivity test product ingredient 14 . Individuals cognitively impair and/or unable give inform consent 15 . Any condition Investigator 's opinion may adversely affect subject 's ability complete study measure may pose significant risk subject</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Total antioxidant capacity</keyword>
	<keyword>SOD</keyword>
	<keyword>8-OHdG</keyword>
	<keyword>8-isoprostane</keyword>
	<keyword>oxLDL</keyword>
</DOC>